Floatz logo

FTC-146

Neuropathic Pain

Stanford UniversitySmall moleculePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

52 Active assets in the Neuropathic Pain cohort.

Asset / SponsorPhaseRating
Pregabalin
Ziauddin University
Phase 4A
Capsaicin
NeurogesX
Phase 3BBB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Ataturk University
Phase 4BBB
Bxcl501
Universidad Juárez Autónoma de Tabasco
Phase 4BBB
LIDOCAINE
Ataturk University
Phase 4BBB

View all 50 →

Same molecule, other indications

FTC-146 is also rated in:

Pediatric DisorderDormant
CC
Indicative ·
47 / 100
View asset →
Nociceptive PainDormant
CC
Indicative ·
47 / 100
View asset →
neuralgiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →